Cobas EGFR Mutation Test regulatory update

The U.K.'s NICE issued guidance recommending the use of 5 diagnostics methods, including 2 tests, to detect EGFR mutations in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC). NICE backed the cobas EGFR Mutation Test from Roche and the therascreen EGFR RGQ PCR Kit from Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN, Venlo, the Netherlands) along with 3 sequencing methods. ...